Skip to main content

1.

Primary and triage screening performance of physician- and self-collected careHPV at ≥1.0 RLU/CO for CIN2+ detection among 2,337 women, compared to VIA and cytology primary screening, and physician-HC2 triage strategies

Primary Screening Triage strategy CIN2+ (N=68) % (95% CI) Colposcopy per CIN2+ (N)
Sensitivity Specificity PPV NPV Youden’s index
HPV, human papillomavirus; RLU/CO, relative light units/cutoff; CIN2+, cervical intraepithelial neoplasia grade 2 or worse; VIA, visual inspection with acetic acid; HC2, Hybrid Capture 2; ASC-H+, atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesions or worse; 95% CI, 95% confidence interval; PPV, positive predictive value; NPV, negative predictive value; ASC-US+, atypical squamous cells of undetermined significance or worse.
Physician- careHPV ≥1.0 RLU/CO None 57 83.8
(73.3–90.7)
88.1
(86.7–89.3)
17.4
(13.7–21.9)
99.5
(99.0–99.7)
71.9
(70.1–73.7)
5.8
ASC-US+ 55 80.9
(70.0–88.5)
95.0
(94.0–95.8)
32.5
(25.9–39.9)
99.4
(99.0–99.6)
75.9
(74.2–77.6)
3.1
VIA 21 30.9
(21.2–42.6)
99.2
(98.7–99.5)
52.5
(37.5–67.1)
98.0
(97.3–98.5)
30.0
(28.1–31.9)
1.9
Self-careHPV ≥1.0 RLU/CO None 49 72.1
(60.4–81.3)
88.2
(86.8–89.5)
15.5
(11.9–19.8)
99.1
(98.5–99.4)
60.2
(58.2–62.2)
6.5
ASC-US+ 45 66.2
(54.3–76.3)
96.4
(95.5–97.1)
35.4
(27.7–44.1)
99.0
(98.4–99.3)
62.6
(60.6–64.6)
2.8
VIA 18 26.5
(17.5–38.0)
99.2
(98.7–99.5)
50.0
(34.5–65.5)
97.8
(97.1–98.3)
25.7
(23.9–27.5)
2.0
Physician-HC2 ≥1.0 RLU/CO None 66 97.1
(89.9–99.2)
86.0
(84.5–87.4)
17.2
(13.7–21.3)
99.9
(99.6–100)
83.0
(81.5–84.5)
5.8
ASC-US+ 63 92.6
(83.9–96.8)
94.4
(93.3–95.2)
33.0
(26.7–39.9)
99.8
(99.5–99.9)
87.0
(85.6–88.4)
3.0
VIA 26 38.2
(27.6–50.1)
99.0
(98.5–99.0)
54.2
(40.3–67.4)
98.2
(97.5–98.6)
37.3
(35.3–39.3)
1.8
Cytology (ASC-H+) None 58 85.3
(75.0–91.8)
97.0
(96.2–97.6)
45.7
(37.3–54.3)
99.5
(99.2–99.8)
82.3
(80.8–83.8)
2.2
VIA None 27 39.7
(28.9–51.6)
95.0
(94.0–95.8)
19.3
(13.6–26.6)
98.1
(97.5–98.6)
34.7
(32.8–36.6)
5.2